DK3408280T3 - Inaktivering af virusser med delipidering - Google Patents

Inaktivering af virusser med delipidering Download PDF

Info

Publication number
DK3408280T3
DK3408280T3 DK17702277.9T DK17702277T DK3408280T3 DK 3408280 T3 DK3408280 T3 DK 3408280T3 DK 17702277 T DK17702277 T DK 17702277T DK 3408280 T3 DK3408280 T3 DK 3408280T3
Authority
DK
Denmark
Prior art keywords
delipidation
inactivation
viruses
delipidation viruses
Prior art date
Application number
DK17702277.9T
Other languages
English (en)
Inventor
Leyla Diaz
Stephen Wu
Original Assignee
Elanco Us Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elanco Us Inc filed Critical Elanco Us Inc
Application granted granted Critical
Publication of DK3408280T3 publication Critical patent/DK3408280T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/10011Arenaviridae
    • C12N2760/10051Methods of production or purification of viral material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151Methods of production or purification of viral material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/10011Arteriviridae
    • C12N2770/10051Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK17702277.9T 2016-01-27 2017-01-20 Inaktivering af virusser med delipidering DK3408280T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662287488P 2016-01-27 2016-01-27
PCT/US2017/014267 WO2017132059A1 (en) 2016-01-27 2017-01-20 Inactivation of viruses by delipidation

Publications (1)

Publication Number Publication Date
DK3408280T3 true DK3408280T3 (da) 2021-01-04

Family

ID=57915178

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17702277.9T DK3408280T3 (da) 2016-01-27 2017-01-20 Inaktivering af virusser med delipidering

Country Status (18)

Country Link
US (1) US10420831B2 (da)
EP (1) EP3408280B1 (da)
JP (1) JP6648286B2 (da)
KR (1) KR102202475B1 (da)
CN (1) CN108602860B (da)
AR (1) AR107262A1 (da)
AU (1) AU2017211040B2 (da)
CA (1) CA3008965C (da)
CL (1) CL2018001978A1 (da)
DK (1) DK3408280T3 (da)
EA (1) EA038712B1 (da)
ES (1) ES2839623T3 (da)
MX (1) MX2018008365A (da)
NZ (1) NZ743601A (da)
PL (1) PL3408280T3 (da)
TW (1) TWI747866B (da)
WO (1) WO2017132059A1 (da)
ZA (1) ZA201804025B (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12226431B2 (en) 2021-09-11 2025-02-18 Porosome Therapeutics, Inc. Aerosol and topical administration of a formulation containing cyclodextrin, quercetin and zinc, in combination or separately, to mitigate infection by enveloped viruses
EP4678649A1 (en) * 2024-07-10 2026-01-14 Roquette Freres Use of substituted cyclodextrin for viral inactivation in biomanufacturing
WO2026013232A1 (en) * 2024-07-10 2026-01-15 Roquette Freres Use of substituted cyclodextrin for viral inactivation in biomanufacturing

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2243994T5 (es) * 1996-04-19 2009-10-29 Grifols Inc. Procedimiento para la inactivacion virica de proteinas de la sangre liofilizadas.
ZA988446B (en) 1997-09-18 2000-03-22 Res Dev Foundation Production of vaccines using arthropod vectored viruses.
AUPQ846900A0 (en) 2000-06-29 2000-07-27 Aruba International Pty Ltd A vaccine
US7407662B2 (en) 2000-06-29 2008-08-05 Lipid Sciences, Inc. Modified viral particles with immunogenic properties and reduced lipid content
US20090017069A1 (en) * 2000-06-29 2009-01-15 Lipid Sciences, Inc. SARS Vaccine Compositions and Methods of Making and Using Them
CU23002A1 (es) 2000-12-01 2004-11-18 Ct Ingenieria Genetica Biotech Método de obtención de agregados antigénicos y su uso en formulaciones
US8613934B2 (en) 2004-03-22 2013-12-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cellular and viral inactivation
JP2006328039A (ja) * 2005-04-26 2006-12-07 Nippo Kagaku Kk 鳥インフルエンザウイルス不活化剤
WO2009014774A1 (en) * 2007-04-06 2009-01-29 Inviragen, Inc. Methods and compositions for live attenuated viruses
GB0720503D0 (en) 2007-10-22 2007-11-28 Angeletti P Ist Richerche Bio New compound
EP2062594A1 (en) * 2007-11-21 2009-05-27 Wyeth Farma, S.A. Bluetongue virus vaccine and immunogenic compositions, methods of use and methods of producing same
CA2871786C (en) * 2012-04-24 2021-11-16 Ohio State Innovation Foundation Compositions and methods for treating and preventing porcine reproductive and respiratory syndrome

Also Published As

Publication number Publication date
KR20180096775A (ko) 2018-08-29
JP2019506860A (ja) 2019-03-14
CN108602860A (zh) 2018-09-28
CN108602860B (zh) 2023-05-26
EA201891371A1 (ru) 2019-01-31
KR102202475B1 (ko) 2021-01-12
JP6648286B2 (ja) 2020-02-14
ES2839623T3 (es) 2021-07-05
AU2017211040B2 (en) 2020-10-08
WO2017132059A1 (en) 2017-08-03
CA3008965A1 (en) 2017-08-03
BR112018014542A2 (pt) 2018-12-11
EP3408280A1 (en) 2018-12-05
TW201733615A (zh) 2017-10-01
AR107262A1 (es) 2018-04-11
TWI747866B (zh) 2021-12-01
US20180360945A1 (en) 2018-12-20
NZ743601A (en) 2020-03-27
ZA201804025B (en) 2020-08-26
AU2017211040A1 (en) 2018-06-28
CA3008965C (en) 2021-04-13
MX2018008365A (es) 2018-09-17
EP3408280B1 (en) 2020-11-25
PL3408280T3 (pl) 2021-05-31
CL2018001978A1 (es) 2018-10-26
US10420831B2 (en) 2019-09-24
EA038712B1 (ru) 2021-10-08

Similar Documents

Publication Publication Date Title
IL280459A (en) Phosphoramidates for the treatment of hepatitis b virus
DK3515937T3 (da) Behandling af refraktorisk migræne
DK3468573T3 (da) Behandling af clostridium difficile infektion
DK3805376T3 (da) Modificeret virus
DK3349758T3 (da) Fremgangsmåder til behandling af arenaviridae-virusinfektioner
DK3684377T3 (da) Fremgangsmåder til behandling af hepatitis-b-infektion
DK3565568T3 (da) Ændret virus
DK3134530T3 (da) Behandling af hyperbilirubinæmi
DK3325662T3 (da) Epigenetisk inaktivering af nmt2
DK3506904T3 (da) Behandling af demens
EP3490574A4 (en) EXPRESSION OF PTEN-LONG WITH ONCOLYTIC VIRUSES
DK3973959T3 (da) Behandling af kolestatisk kløe med seladelpar
DK3436074T3 (da) Thiazolidforbindelser til behandling af virale infektioner
DK3497892T3 (da) Komprimering af videresendelsestabeller
DK3294740T3 (da) Hidtil ukendte sulfonimidoylpurinonforbindelser og derivater til behandling og profylakse af virusinfektion
DK3307267T3 (da) Behandling af multipel sklerose
DK3137078T3 (da) Behandling af hepatitis delta-virusinfektion
DK3370723T3 (da) Behandling af hepatitis delta-virusinfektion
DK2897382T3 (da) Forbedring af binaural kilde
DK3274340T3 (da) Hæmmere af hepatitis c-viruspolymerase
DK3297619T3 (da) Terapeutiske anvendelser af L-4-chlorkynurenin
DK3279312T3 (da) Biobeskyttelse af mejeriprodukter
DK3368044T3 (da) Behandling af hepatisk steatose-relateret oligo-ovulation
DK3580197T3 (da) Oprensning af pleuromutilin
DK3201323T3 (da) Modificering af bakteriofag